Skip to main content
. Author manuscript; available in PMC: 2013 May 15.
Published in final edited form as: J Immunol. 2012 Apr 18;188(10):4913–4920. doi: 10.4049/jimmunol.1103668

Figure 5. DNP treatment suppresses joint inflammation via IDO in a model of immune-mediated arthritis.

Figure 5

B6 and IDO1-KO mice (n=5) were immunized and boosted with mBSA, and arthritis was induced after 21 days by intra-articular mBSA injection (see Methods). pAT/PEI nanoparticles were administered five times (i/v, 20, 21, 22, 24 26 days after initial mBSA immunization). Some pAT/PEI-treated B6 mice also received oral 1MT starting two days before initial mBSA immunization. Arthritis progression was monitored by assessing cumulative joint swelling 7 days after mBSA challenge (A) represented as area under curve (AUC), and neutrophil infiltration into joints 1 day after local mBSA challenge (B). IL-6 (C) and IL-17 (D) cytokine levels in inflamed dLN cells were assessed by multiplex analysis. Data are representative of two independent experiments with 3–5 mice/group; statistical significance (*) was estimated using Student’s t test by combining both experiments.